Back to Journals » Vascular Health and Risk Management » Volume 4 » Issue 2

Management of venous thromboembolism in patients with cancer: role of dalteparin

Authors Linkins L

Published 11 April 2008 Volume 2008:4(2) Pages 279—287

DOI https://doi.org/10.2147/VHRM.S2132


Lori-Ann Linkins

Department of Hematology and Thrombosis, McMaster University, Hamilton, Ontario, Canada

Abstract: Cancer is a major risk factor for the development of venous thromboembolism (VTE). Conventional anticoagulant therapy with a vitamin K antagonist is more problematic in cancer patients due to an increased risk of recurrent VTE, and an increased risk of anticoagulant-related bleeding. In recent years, there has been a shift toward treating cancer patients with VTE with extended duration dalteparin. Dalteparin, a low-molecular-weight heparin, has been shown to be more effective, and as safe as conventional anticoagulant therapy, in cancer patients with VTE. This paper will (a) review the relationship between cancer and VTE, and (b) provide an overview of the role of dalteparin in the management of VTE in patients with cancer.

Keywords: dalteparin, cancer, venous thromboembolism

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]